O’Hara-based Thar Pharmaceuticals Inc. has been sold to a German company, three months after Thar announced plans for an initial public offering.

Pharmaceutical research and development company Grunenthal Group, based in Aachen, Germany, purchased Thar Pharmaceuticals, which is a spinoff of Thar Technologies Inc. Grunenthal is an independent, family-owned pharmaceutical company that has offices in 32 countries and sells products in 155 countries. Terms of the deal were not disclosed.

A Thar spokeswoman said the O’Hara company had abandoned plans for an IPO in favor of a sale.

Thar Pharmaceuticals is a clinical stage, specialty drug company that focuses on pharmaceuticals that are already on the market.

Advertise with us

Thar founder Lalit Chordia, who will remain with O’Hara-based Thar Process Inc., said he would turn his attention to more effective non-narcotic drugs than are already available for pain relief, including cannabinoids and meloxicam, which is often prescribed for arthritis. Thar Process, another spinoff of Thar Technologies, planned to use supercritical fluid technology to extract, separate and reconstitute cannabinoids for use in medications.

Pennsylvania is among 28 states and the District of Columbia that have legalized marijuana for medical purposes. The state Health Department is preparing temporary regulations for the drug.

“With today’s growing acceptance and legal use of marijuana for medicinal purposes, we see opportunity in extracting and reconstitution cannabinoids such as THC and CBD with a green process that avoids the use of toxic solvents,” Mr. Chordia said in a prepared statement.

Kris B. Mamula:kmamula@post-gazette.com, or 412-263-1699